Global Molecular Diagnostics for STD Market Size, Share, Growth and Trends Report Segmented by Product (Instruments, Consumables, Software & Services), Application (CT/NG, Syphilis, Gonorrhoea Testing), Mode of Testing (Laboratory, PoC), End User & Regional Forecast to 2031

The global molecular diagnostics for STD market size is set to grow at an 8% CAGR over the next 5 years. Key drivers include the rising prevalence of sexually transmitted infections (STIs), increasing number of screening programs led by the government, transition from conventional diagnostics to molecular techniques, growing emphasis on high-sensitivity and early-stage detection, and supportive public health policies and funding initiatives. To learn more about the research report, download a sample report. 

Molecular diagnostics for sexually transmitted diseases (STDs) refers to highly sensitive laboratory-based and point-of-care techniques that are designed to detect pathogen-specific nucleic acids to identify infections such as chlamydia, gonorrhea, syphilis, human papillomavirus (HPV), and HIV. These methods provide better sensitivity, accuracy, and faster results compared to traditional cultures, which are often time-consuming or unable to cultivate certain pathogens, thereby allowing for early detection of asymptomatic cases and reduced transmission. Key technologies used for detection include polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS). The market includes instruments, reagents, assay kits, and associated software & services used across hospitals, diagnostic laboratories, and decentralized care settings.

Rising prevalence of sexually transmitted infections

The increasing burden of sexually transmitted diseases (STDs) globally continues to drive testing demand. These infections, particularly chlamydia and HPV, often remain asymptomatic in their early stages but can cause severe reproductive health issues, including infertility and ectopic pregnancies, thereby necessitating routine screening for effective disease control.

Global health bodies continue to report a steady rise in STD cases. According to an article published by the WHO, more than 1million people aged 15-49 acquire sexually transmitted infections (STIs) every day globally, thereby creating a sustained market for advanced diagnostic solutions for STDs.Thisaccelerating rise is forcing a surge in testing volume, with public health agencies having expanded screening recommendations, especially among high-risk populations such as sexually active adolescents and young adults, to break chains of transmission and reduce long-term health complications.

Molecular diagnostics tests, such as ion Tests (NAATs), are increasingly preferred in these programs due to their high sensitivity and ability to detect infections even at low pathogen loads. As surveillance programs become more structured and testing frequency increases, laboratories are adopting automated molecular platforms, allowing for higher throughput, faster turnaround times, and reduced human error in handling large sample loads.Additionally, increased awareness campaigns and government-led screening initiatives emphasize on the need for regular screening, which in turn has led to high demand for testing services. Furthermore, increased government funding for screening programs in high-risk areas has boosted the demand for molecular diagnostic products, thereby creating a sustained market for advanced diagnostic solutions for STDs.

To learn more about this report, download the PDF brochure

Shift toward multiplex and high-throughput testing

Healthcare providers are rapidly adopting multiplex assays capable of detecting multiple pathogens from a single swab or sample. This shift is driven by the high prevalence of asymptomatic co-infections, where a patient can have multiple infections simultaneously. This growing burden of co-infections, coupled with the need for accurate antimicrobial stewardship, has increased the demand for comprehensive screening panels, further accelerating the adoption of multiplex testing approaches.

Molecular diagnostics, especially real-time PCR, deliver high sensitivity and rapid results, often within a few hours to one day, offering a better alternative to traditional culture-based methods. Moreover, these high-throughput systems now feature automated workflows, thereby allowing large laboratories to process high volumes of samples with minimal manual intervention, ensuring high consistency and reduced turnaround times.

These scalable systems are critical in public health screenings, helping to detect asymptomatic infections, that if left untreated, can lead to serious complications like infertility or cancer. Centralized labs, therefore, leverage these technologies to support national and regional sexual health surveillance and control programs. Moreover, the ability to consolidate testing workflows into a single platform reduces overall costs per test and enables targeted treatment rather than empirical therapy.

To learn more about this report, download the PDF brochure

Product Type Segment Outlook

Themolecular diagnostics for STD market is categorized by product into instruments, consumables (reagents & kits), and software & services. Reagents and assay kits represent the largest share within the product segment, as they are consumables required for every test performed in the different healthcare settings. This segment includes NAATs and PCR kits, which can detect multiple infections with better sensitivity, and high demand for testing, which ensures recurring revenue generation for this category. Instruments hold a significant market share, as they are essential for enabling high-throughput and automated workflows in laboratories, along with increasing adoption of rapid, portable molecular platforms. Software & services solutions are gaining relevance as laboratories adopt data management systems to handle increasing testing volumes and integrate diagnostic reswith electronic health records.

Regional Outlook: North America maintains its leading position in molecular diagnostics for STD market through robust diagnostic infrastructure and widespread screening

North America holds the major share of the molecular diagnostics for STD market, due to rising awareness of STIs supported by well-established screening programs and advanced molecular diagnostic technologies. Moreover, the substantial investments in R&D and widespread adoption of automated laboratory infrastructure support high testing volumes, thereby further strengthening the region's growth.

Following North America, Europe holds a significant share of the market, with high demand for testing driven primarily by structured public health initiatives and the increasing integration of molecular diagnostics into routine screening protocols. Further, the rising prevalence of STDs and regulatory alignment across countries in tgion have facilitated technology adoption.

The Asia-Pacific region is expected to experience the fastest growth, driven by rising awareness of STIs, expanding access to healthcare, and increasing government-led screening campaigns. Countries in this region are also investing in advanced laboratory infrastructure and decentralized & point-of-care testing solutions, thereby further strengthening the region's penetration in the market

Competitive Landscape Analysis

The global molecular diagnostics for STD market is marked by the presence of established and emerging market players such as BD (Becton, Dickinson and Company) (US); F. Hoffmann-La Roche Ltd (Switzerland); Hologic Inc. (US); Abbott Laboratories (US); Cepheid (Danaher Corporation) (US); Qiagen N.V. (Netherlands); bioMrieux SA (France); Thermo Fisher Scientific, Inc. (US); Seegene Inc. (South Korea); and DiaSorin S.p.A (Italy), among others.

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the molecular diagnostics for STD market

Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In March 2025, Visby Medical received FDA De Novo authorization for its Women-s Sexual Health Test, a fully at-home molecular diagnostic test capable of detecting chlamydia, gonorrhoea, and trichomoniasis using PCR-based technology with results available in 30 minutes
• In January 2025, Roche announced that the cobas liat sexually transmitted infection (STI) multiplex assay panels, including CT/NG and CT/NG/MG, received FDA clearance and CLIA waiver, enabling rapid PCR-based detection of chlamydia, gonorrhoea, and My genitalium in approximately 20 minutes to support testing in decentralized and point-of-care settings, improving timely diagnosis and treatment decisions
• In January 2025, Abbott Molecular announced that the simpli-COLLECT STI Test received FDA clearance, enabling detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium from home-collected specimens that are shipped to a clinical laboratory for testing, supporting expanded access to molecular STD diagnostics through at-home sample collection paired with centralized laboratory testing
• In February 2023, Thermo Fisher Scientific announced the launch of the TrueMark STI Select Panel, a PCR-based assay designed for research use to detect Neisseria gonorrhoeae, Mycoplasma genitalium, Chlamydia trachomatis, and Trichomonas vaginalis in a single test, expanding its molecular diagnostics portfolio for multiplex STD detection

Global Molecular Diagnostics for STD Market Segmentation

This report by Medi-Tech Insights provides thesize of the global molecular diagnostics for STD market at theregional and country-level from 2024 to 2031. The report further segments the market by product, application, mode of testing, and end user.

• Market Size & Forecast (2024-2031), By Product, USD Billion
  • Instruments
  • Consumables (Reagents and kits)
  • Software & Services

• Market Size & Forecast (2024-2031), By Application, USD Billion
  • CT/NG Testing
  • Syphilis Testing
  • Gonorrhoea Testing
  • HSV Testing
  • HPV Testing
  • HIV Testing
  • Trichomonas
  • Ureaplasma + Mycoplasma
  • Others